Trevena, Inc. to Present at September Virtual Investor Conferences
- H.C. Wainwright: 22nd Annual Global Investment Conference -
September 14th
- Cantor Fitzgerald Virtual Global Healthcare Conference -
September 17th
-Oppenheimer Fall Healthcare Life Sciences & MedTech Summit -
September 23rd
CHESTERBROOK, Pa., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below:
| H.C. Wainwright: 22nd Annual Global Investment Conference | |
| Title: | Trevena (TRVN) Fireside Chat |
| Date: | Monday, September 14th, 2020 |
| Time: | 2:00 – 2:20 p.m. Eastern Time |
| Presenters: | Carrie Bourdow, President & Chief Executive Officer |
| Mark Demitrack, M.D., SVP & Chief Medical Officer | |
| Cantor Fitzgerald Virtual Global Healthcare Conference | |
| Title: | Trevena (TRVN) Fireside Chat |
| Date: | Thursday, September 17th, 2020 |
| Time: | 2:00 – 2:30 p.m. Eastern Time |
| Presenter: | Carrie Bourdow, President & Chief Executive Officer |
| Oppenheimer Fall Healthcare Life Sciences & MedTech Summit | |
| Title: | Trevena (TRVN) Virtual Presentation |
| Date: | Wednesday, September 23rd, 2020 |
| Time: | 11:40 a.m. – 12:20 p.m. Eastern Time |
| Presenter: | Bob Yoder, SVP & Chief Business Officer |
Webcast Links:
A replay of the webcast will be accessible on the Events page of the Investors section on the Company’s website at .
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.
For more information, please visit
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates, commercialization of approved drug products and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “objective,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “ongoing,” or the negative of these terms or similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the commercialization of any approved drug product, the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials of any of the Company’s investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company’s assessment of the discussions with the FDA or other regulatory agencies about any and all of its programs; uncertainties related to the commercialization of OLINVYK; available funding; uncertainties related to the Company’s intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.
For more information, please contact:
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
(617) 430-7576
Company Contact:
Bob Yoder
SVP and Chief Business Officer
Trevena, Inc.
(610) 354-8840
